Glyburide, a medication for treating type 2 diabetes mellitus (T2DM), also acts as an NLRP3 inhibitor, reducing the expression of pro-inflammatory cytokines and decreasing the number of osteoclasts in diabetes-induced fractures, while simultaneously promoting endochondral bone formation and mineralization, thereby accelerating fracture healing [198]. Here, NLRP3 is linked to type 2 diabetes mellitus.